Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
Epistemonikos ID: 3bb93b4973c4b4d68534ccd65efcfd4b50c4a7b0
First added on: Feb 19, 2024